

# Interleukin-12 supports in vitro self-renewal of long-term hematopoietic stem cells

Shanshan Zhang<sup>a</sup>, Maiko Morita<sup>b</sup>, Zhao Wang<sup>a</sup>, Jun Ooehara<sup>c</sup>, Sen Zhang<sup>a</sup>, Miner Xie<sup>a</sup>, Haitao Bai<sup>a</sup>, Wenying Yu<sup>a</sup>, Xiaofang Wang<sup>a</sup>, Fang Dong<sup>a</sup>, Jinhong Wang<sup>a</sup>, Shihui Ma<sup>a</sup>, Satoshi Yamazaki<sup>b,c,\*</sup>, Hideo Ema<sup>a,\*</sup>

<sup>a</sup>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; <sup>b</sup>Project Division of Advanced Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan; <sup>c</sup>Laboratory of Stem Cell Therapy, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan

## Abstract

Hematopoietic stem cells (HSCs) self-renew or differentiate through division. Cytokines are essential for inducing HSC division, but the optimal cytokine combination to control self-renewal of HSC in vitro remains unclear. In this study, we compared the effects of interleukin-12 (IL-12) and thrombopoietin (TPO) in combination with stem cell factor (SCF) on in vitro self-renewal of HSCs. Single-cell assays were used to overcome the heterogeneity issue of HSCs, and serum-free conditions were newly established to permit reproduction of data. In single-cell cultures, CD150<sup>+</sup>CD48<sup>-</sup>CD41<sup>-</sup>CD34<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>lineage<sup>-</sup> HSCs divided significantly more slowly in the presence of SCF+IL-12 compared with cells in the presence of SCF+TPO. Serial transplantation of cells from bulk and clonal cultures revealed that TPO was more effective than IL-12 at supporting in vitro self-renewal of short-term (<6 months) HSCs, resulting in a monophasic reconstitution wave formation, whereas IL-12 was more effective than TPO at supporting the in vitro self-renewal of long-term (>6 months) HSCs, resulting in a biphasic reconstitution wave formation. The control of division rate in HSCs appeared to be crucial for preventing the loss of self-renewal potential from their in vitro culture.

**Keywords:** Ex vivo expansion, Hematopoietic stem cells, Interleukin-12, Self-renewal

## 1. INTRODUCTION

Most adult bone marrow HSCs reside in a quiescent state at any given time and infrequently cycle for self-renewal or differentiation into blood lineages.<sup>1–3</sup> Cytokines play essential roles regarding when hematopoietic stem cells (HSCs) begin cycling.<sup>4</sup> Previous studies have revealed that interleukin (IL)-3, IL-6, IL-11,<sup>5–7</sup> thrombopoietin (TPO),<sup>8</sup> and granulocyte-colony stimulating factor,<sup>9</sup> in combination with stem cell factor (SCF), can drive HSCs into the cell cycle. These cytokines generally share intracellular signal transduction pathways.

However, whether these cytokines have different effects on HSC self-renewal and differentiation is currently unknown.

There is a functional heterogeneity among HSC populations.<sup>10–17</sup> In the mouse, various classifications of HSC subsets with different names have been proposed.<sup>13,14,16,18</sup> In this study, short-term (ST) and long-term (LT) HSCs were defined at the clonal level and used in subsequent experiments. ST-HSCs reconstituted myeloid, B-lymphoid, and T-lymphoid lineages at a specific time, and their myeloid reconstitution levels decreased by 6 months after transplantation. The myeloid reconstitution levels of LT-HSCs were maintained or increased for 6 months or longer after transplantation. Moreover, myeloid reconstitution alone is sufficient to detect LT-HSCs, and lymphoid reconstitution may not be essential for LT-HSCs.<sup>19</sup>

The IL-12 family comprises IL-12, IL-23, IL-27, and IL-35.<sup>20</sup> Their subunits are shared to form heterodimeric ligands and their receptors. IL-27 directly supports myeloid differentiation but not self-renewal in HSCs.<sup>21</sup> Neither IL-23 nor IL-35 seems to have any effect on HSCs (HE, unpublished data, 2017). Two decades ago, IL-12 in combination with SCF, Flt3 ligand, or IL-11 was shown to stimulate hematopoietic progenitors.<sup>22–25</sup> However, whether IL-12 acts directly on transplantable HSCs and supports their self-renewal and/or differentiation has never been definitively examined.

We have previously shown that TPO and SCF together support in vitro self-renewal division in serum-free cultures to some extent.<sup>8,26,27</sup> In this study, we compared the direct effects of IL-12 and TPO in combination with SCF on ST- and LT-HSC fates at the single-cell level. We found that both TPO and IL-12 support the self-renewal of ST- and LT-HSCs in culture, but that IL-12 is superior at supporting LT-HSC self-renewal.

\* Address correspondence: Hideo Ema, MD, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Rd, Tianjin 300020, China. E-mail address: hema@ihcams.ac.cn (H. Ema), Satoshi Yamazaki, PhD, Project Division of Advanced Regenerative Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Tokyo 108-8639, Japan. E-mail address: y-sato4@ims.u-tokyo.ac.jp (S. Yamazaki).

Shanshan Zhang, Maiko Morita, and Zhao Wang have contributed equally to this work.

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

Blood Science, (2019) 1, 92-101

Received January 24, 2019; Accepted February 7, 2019.

<http://dx.doi.org/10.1097/BS9.000000000000002>

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Association for Blood Sciences. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

## 2. METHODS

### 2.1. Mice

C57BL/6 (B6) mice were purchased from Beijing HFK Bioscience, Co. (Beijing, China) or Japan SLC (Shizuoka, Japan). Ly5 congenic B6 mice (B6-Ly5.1) were bred and maintained at the State Key Laboratory of Experimental Hematology or purchased from Sankyo Lab (Tsukuba, Japan). Eight- to 10-week-old female mice were used for all experiments. All experimental protocols using mice were approved by the institutional animal care and use committees at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and at the Institute of Medical Science, University of Tokyo.

### 2.2. Isolation of HSC1 cells

Bone marrow cells were obtained from the femora, tibiae, and iliac crests of 8- to 10-week-old female B6 or B6-Ly5.1 mice. c-Kit-positive cells were enriched by anti-c-Kit antibody-conjugated MACS beads (Miltenyi Biotechnology, Germany) and stained with a lineage cocktail consisting of allophycocyanin (APC)-eFluor 780-conjugated anti-B220 (RA3-6B2, eBioscience, Waltham, MA), Gr-1 (RB6-8C5, eBioscience), and Ter-119 (TER-119, eBioscience) antibodies. Cells were also stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD34 (RAM34, eBioscience), APC-conjugated anti-c-Kit (2B8, eBioscience), phycoerythrin-cyanine 7 (PE-Cy7)-conjugated anti-Sca-1 (D7, eBioscience), brilliant violet 421-conjugated anti-CD48 (HM48-1, eBioscience), PE-conjugated anti-CD150 (TC15-12F12.2, Biolegend), and PerCP-eFluor 710-conjugated anti-CD41 (eBioMWR30, eBioscience) antibodies. CD150<sup>+</sup>CD41<sup>-</sup>CD48<sup>-</sup>CD34<sup>-</sup>c-Kit<sup>+</sup>Sca1<sup>+</sup>Lineage<sup>-</sup> (CD150<sup>+</sup>41<sup>-</sup>34<sup>-</sup>KSL) cells, which were designated HSC1, were sorted with a FACS Aria III (BD Biosciences).

### 2.3. Serum-free culture components

S-Clone (Sanko Junyaku, Japan) had previously been provided in a package of SF-O3 medium; the supplement contained insulin, transferrin, bovine serum albumin (BSA), and other factors. Recently, BSA was excluded from the manufacturer's package. Thus, we used rHSA purchased from Albumin Bioscience (Huntsville, AL) or Sigma-Aldrich. Dulbecco Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, Ham F-12 medium, insulin (I), transferrin (T), selenium (S), ITS, and ITS with ethanolamine (ITS-X, 51500-056) were purchased from Thermo Fisher Scientific (Waltham, MA).

### 2.4. New standard serum-free medium

We optimized all of our serum-free culture conditions. Our new standard serum-free medium consisted of 0.5 mg/mL rHSA (Albumin Bioscience, 1001), 1 × ITS-X (Thermo Fisher Scientific, 51500-056), 10 mM HEPES (Sigma Aldrich, H0887), 0.1 mM MEM nonessential amino acids (Thermo Fisher Scientific, 11140050), 2 mM L-glutamine (Thermo Fisher Scientific, 25030081), 0.055 mM 2-mercaptoethanol (Thermo Fisher Scientific, 21985023), and 0.5 mg/mL streptomycin/penicillin (Thermo Fisher Scientific, 10378016) in Ham F-12 medium (Thermo Fisher Scientific, 21700026).

### 2.5. Single-cell culture

Briefly, 60 HSC1 cells were individually sorted into a 96-well U-bottom plates, with each well receiving 200 μL of the new

standard serum-free medium supplemented with 50 ng/mL recombinant murine SCF (Peprotech, 250-03), 50 ng/mL recombinant murine TPO (Peprotech, 315-14), and 50 ng/mL recombinant murine IL-12 (Peprotech, Rocky Hill, NJ, 210-12). Single cells were cultured at 37°C in a humidified atmosphere with 5% CO<sub>2</sub> for 7 days. The cell numbers in each well was visually counted every day using an inverted microscope. The first division kinetics was obtained based on the cumulative number of wells where ≥2 cells were found during 7 days of culture. The second-division kinetics were obtained based on the cumulative number of wells where ≥3 cells were found. The third-division kinetics were obtained based on the cumulative number of wells where ≥5 cells were found.

### 2.6. Serial competitive repopulation

Competitive repopulation was performed on 10 to 40 test donor cells (test cells) purified from the bone marrow of B6-Ly5.1 mice together with 5 × 10<sup>5</sup> or 10 × 10<sup>5</sup> bone marrow cells (competitor cells) from B6 mice. When the cultured cells were tested, 10 to 40 cells were cultured in serum-free medium for 7 days. SCF, TPO, and IL-12 were used at 50 ng/mL each. Cultured cells were mixed with competitor cells and injected into B6 mice irradiated twice at a dose of 4.75 Gy after a 3-hour interval (total 9.5 Gy). Peripheral blood cells from the recipient mice were analyzed at the indicated time points after transplantation.

For the peripheral blood analysis, red blood cells were lysed with buffer containing 0.15 M NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, and 0.1 mM EDTA in water (pH 7.2). Cells were stained with FITC-conjugated anti-CD45.1 (A20, eBioscience), PE-conjugated anti-CD45.2 (104, eBioscience), PE-Cy7-conjugated anti-CD4 (GK1.5, eBioscience), APC-conjugated anti-CD8a (53-6.7, eBioscience), PerCP-Cy5.5-conjugated anti-B220 (RA3-6B2, eBioscience), and APC-eFluor780-conjugated anti-Mac-1/Gr-1 (M1/70 and RB6-8C5, eBioscience) antibodies. Cells were analyzed on a Canto II (Becton Dickinson, Franklin Lakes, NJ). The percentage of test donor-derived cells (% test cells) was calculated with the following formula: (% Ly5.1<sup>+</sup> cells) × 100 / (% Ly5.1<sup>+</sup> test cells + % Ly5.2<sup>+</sup> cells). When the percentage of test cells was 0.5 or greater, the recipient mouse hematopoietic system was considered to be reconstituted with test cell-derived cells (positive mice). Mac-1/Gr-1<sup>+</sup> cells were considered to be of a myeloid lineage. B220<sup>+</sup> cells were considered to be of a B-lymphoid lineage. CD4<sup>+</sup> and CD8<sup>+</sup> cells were considered to be of a T-lymphoid lineage.

For secondary transplantation, bone marrow cells were harvested from the femora, tibiae, and iliac crests from each recipient mouse. Bone marrow cells from all recipient mice were pooled, and a half femur-equivalent or 2 × 10<sup>7</sup> bone marrow cells were transplanted into lethally irradiated mice. Peripheral blood from the recipient mice was analyzed at the indicated time points after transplantation. For further serial transplantation, the same protocol was used.

### 2.7. Single-cell transplantation

Single HSC1 cells were sorted from B6-Ly5.1 murine bone marrow and transplanted into lethally irradiated B6 mice, along with 5 × 10<sup>5</sup> bone marrow cells from a B6 mouse. Single HSC1 cells were cultured in the new standard serum-free medium with the indicated cytokines for 7 days and transplanted into lethally irradiated B6 mice along with 5 × 10<sup>5</sup> bone marrow cells from a B6 mouse. For secondary transplantation, 2 × 10<sup>7</sup> bone marrow cells from each recipient mouse were transplanted into a lethally irradiated mouse.

## 2.8. Single-cell RT-PCR

Single cells were sorted into 48 wells of a 96-well plate where each well contained 10  $\mu\text{L}$  of reverse transcription and specific target amplification mixture consisting of 2.5  $\mu\text{L}$  0.2 $\times$  primers containing all 48 sets of primers, 5.0  $\mu\text{L}$  2 $\times$  reaction mix, 0.5  $\mu\text{L}$  Superscript III, and 2.0  $\mu\text{L}$  Tris-EDTA buffer. Reverse transcription was performed at 50°C for 15 minutes. The samples were incubated at 95°C for 2 minutes, followed by 22 cycles of 95°C for 15 seconds and 60°C for 4 minutes. Five microliters from each of the samples was mixed with 20  $\mu\text{L}$  of Tris-EDTA. Then, 2.7  $\mu\text{L}$  of the diluted samples was mixed with 3.0  $\mu\text{L}$  Taqman universal PCR master mix (Applied Biosystems) and 0.3  $\mu\text{L}$  sample loading buffer (for a total of 6.0  $\mu\text{L}$  sample loading mix). After 3.0  $\mu\text{L}$  of 20 $\times$  of each set of primers was mixed with 3.0  $\mu\text{L}$  of assay loading reagent (a total of 6.0  $\mu\text{L}$  assay loading mix), 5  $\mu\text{L}$  of the sample loading mix and 5  $\mu\text{L}$  of the assay loading mix were applied to a 48-chip array, and 48 $\times$ 48 reactions were prepared by an integrated fluidics circuit controller. The chip was set on a Fluidigm BioMark and incubated at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Data were analyzed with BioMark Real-time PCR analysis software (Fluidigm, San Francisco, CA). The PCR primers purchased from Thermo Fisher are listed in Supplemental Table 1 (<http://links.lww.com/BS/A1>). When threshold cycle values (Ct) were <27.65, cells were considered to express the gene (positive cells).

## 2.9. Statistical analysis


To test whether the mean of a variable differed between 2 groups, unpaired *t* test or Mann-Whitney test was performed. To compare 3 or more groups, nonparametric ANOVA testing was performed.

## 3. RESULTS

### 3.1. Ex vivo expansion of ST-HSCs and LT-HSCs

We prepared test donor cells (test cells) from B6-Ly5.1 mice and competitor cells from B6-Ly5.2 mice in this study. Initially, we used CD34<sup>low</sup>, c-Kit<sup>+</sup>, Sca-1<sup>+</sup>, and lineage<sup>-</sup> (CD34<sup>-</sup>KSL) cells<sup>28,29</sup> as our HSC-enriched population. Forty freshly isolated CD34<sup>-</sup>KSL cells were transplanted into lethally irradiated mice along with  $1 \times 10^6$  competitor cells, and bone marrow cells from the recipient mice were serially transplanted 3 more times. Figure 1 shows all results obtained from serial competitive repopulation. The percentage of total test cell-derived cells in the peripheral blood (% test cells) showed that varying degrees of reconstitution occurred among the primary recipients, but these gradually decreased over the serial transplantation.

To compare the effects of IL-12 with TPO in combination with SCF on HSCs in culture, 40 CD34<sup>-</sup>KSL cells were cultured in serum-free SF-O3 medium with its supplement and BSA for 7 days and subsequently transplanted into lethally irradiated mice, along with  $1 \times 10^6$  competitor cells. The percentage of test cells 1 month after primary transplantation in SCF+TPO culture was significantly greater than that in freshly isolated cells and SCF+IL-12 culture. The levels of reconstitution given by SCF+TPO cultures but not SCF+IL-12 cultures remained significantly greater than those given by freshly isolated cells after secondary transplantation. Overall, however, the reconstitution levels of SCF+TPO cultures ultimately decreased. As a result, a monophasic wave of reconstitution was observed. In contrast, the reconstitution levels given by SCF+IL-12 cultures decreased after primary transplantation. But, low levels of reconstitution were



**Figure 1.** Effect of IL-12 treatment on HSCs revealed by serial competitive repopulation assays. Forty CD34<sup>-</sup>KSL cells were transplanted into 10 lethally irradiated mice along with  $1 \times 10^6$  bone marrow competitor cells (freshly isolated cells). Forty CD34<sup>-</sup>KSL cells were cultured with SCF+TPO or SCF+IL-12 in SF-O3 medium, its supplement, and BSA for 7 days and then transplanted into 10 lethally irradiated mice along with  $1 \times 10^6$  bone marrow competitor cells. Peripheral blood samples from the recipients were analyzed at 1, 3, and 5 months (indicated as 1-1, 1-3, and 1-5, respectively) after transplantation. The percentage of test cells is equal to the percentage of Ly5.1+ cells in the peripheral blood. For serial transplantation, bone marrow cells were collected from one femur from all the surviving recipients and pooled for each group. Bone marrow cells equivalent to those in a half femur were transplanted into 5 lethally irradiated mice. Peripheral blood from the recipients was analyzed 1, 3, and 5 months (indicated as 2-1, 2-3, and 2-5, respectively); 1 and 5 months (indicated as 3-1 and 3-5, respectively); and 1, 3, and 5 months (indicated as 4-1, 4-3, and 4-5, respectively) after secondary, tertiary, and quaternary transplantation, respectively. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001 (nonparametric ANOVA). BSA = bovine serum albumin; HSC = hematopoietic stem cells; IL = interleukin; SCF = stem cell factor; TPO = thrombopoietin.

maintained after secondary transplantation. Surprisingly, the reconstitution levels increased 5 months after tertiary transplantation. As a result, a biphasic wave of reconstitution was observed. It would be interesting to determine whether different types of HSCs contributed to the formation of these monophasic and biphasic waves. Nevertheless, both ST (<6 months) and LT (>6 months) reconstitution activities were increased in SCF+TPO and SCF+IL-12 cultures, but their reconstitution kinetics markedly differed.

### 3.2. Further enrichment of LT-HSCs

We attempted to reproduce our important transplantation results described; however, it was difficult to do so. There have been many such cases in previous studies as well.<sup>5</sup> Thus, we sought to address two fundamental problems in HSC culture: the heterogeneity of HSCs among purified cells, and batch-to-batch differences of serum-free media. When these problems are solved, it should be possible to clonally analyze cultured cells, enabling the dissection of the reconstitution waves.

To reduce heterogeneity in the HSCs, CD150<sup>+</sup>CD41<sup>-</sup>CD34<sup>-</sup>KSL (CD150<sup>+</sup>41<sup>-</sup>34<sup>-</sup>KSL) cells<sup>16</sup> were used as a more purified source of HSCs. CD150<sup>+</sup>41<sup>-</sup>34<sup>-</sup>KSL and CD150<sup>-</sup>41<sup>-</sup>34<sup>-</sup>KSL cells are subpopulations within CD34<sup>-</sup>KSL cells and were named HSC1 and HSC2, respectively, provided in the Supplemental Figure 1 (<http://links.lww.com/BS/A2>). We first compared the HSC1 and HSC2 cells with CD34<sup>-</sup>KSL cells by transplantation assay. Forty CD34<sup>-</sup>KSL cells, 20 HSC1 cells, or 20 HSC2 cells were transplanted into lethally irradiated mice, along with  $1 \times 10^6$  competitor cells. These cells were cultured with SCF+TPO in SF-O3 medium containing its supplement for 7 days and then similarly transplanted. Figure 2 shows 12-month follow-up monitoring for the recipient mice after transplantation. LT (>6 months) reconstitution was observed after transplantation with CD34<sup>-</sup>KSL cells. A comparable level of LT reconstitution was observed after transplantation with HSC1 cells. The reconstitution levels of freshly isolated HSC1 cells were significantly greater than those of freshly isolated HSC2 cells, supporting our previous observations.<sup>16</sup> Interestingly, the ST repopulation activities at 1 month after transplantation were significantly increased in CD34<sup>-</sup>KSL cells and HSC1 cells but not


HSC2 cells after culture. Varying levels of LT reconstitution activities were detected in the cultured cells derived from CD34<sup>-</sup>KSL cells and HSC1 cells. The reconstitution levels of cultured HSC1 cells were significantly greater than those of cultured HSC2 cells. Both ST- and LT-HSC activities in HSC1 cells were enhanced by in vitro culture. Based on these data, we concluded that the HSC activities of CD34<sup>-</sup>KSL cells both before and after culture are well-represented by HSC1 cells. If HSC1 cells were used, more LT-HSCs would generate ST-HSCs and LT-HSCs in culture.

### 3.3. New serum-free culture conditions

This study next sought to address the problems associated with serum-free media conditions. To culture HSCs, many researchers routinely use commercially available serum-free media. Most of these media contain BSA, resulting in batch-to-batch variation.<sup>27</sup> In this study, we attempted to establish our own serum-derived protein-free medium in which all components were chemically defined.

A serum-free medium called S-Clone, consisting of SF-O3 medium, its supplement, BSA, and other components, has regularly been used as one of the best formulations of serum-free media.<sup>16,26,30,31</sup> The BSA previously included in the S-Clone package has recently been removed and is now provided separately by the company. We attempted to replace BSA with recombinant human serum albumin (rHSA).<sup>27</sup> In this study, 3 different batches of rHSA were tested with competitive repopulation assays. Ten HSC1 cells were transplanted into lethally irradiated mice, along with  $5 \times 10^5$  competitor cells. Ten HSC1 cells were also cultured with SCF+TPO in SF-O3 medium, its supplements, and 0.1 or 0.5 mg/mL rHSA. As shown in Supplemental Figure 2 (<http://links.lww.com/BS/A3>), regardless of the different batches of rHSA used, similar degrees of ST and LT reconstitution activities were observed in the groups of cultured cells with 0.5 mg/mL rHSA; however, reconstitution activities in cultured cells with 0.1 mg/mL rHSA-1 and -2 were significantly lower than those with 0.5 mg/mL rHSA-1 and -2, respectively.


We next compared the following basic media formulations and their mixtures: SF-O3, DMEM, RPMI 1640, and Ham F12




**Figure 2.** HSC1 cells represent CD34<sup>-</sup>KSL cells in culture. Forty CD34<sup>-</sup>KSL cells, 20 CD150<sup>+</sup>41<sup>-</sup>34<sup>-</sup>KSL cells (HSC1), or 20 CD150<sup>-</sup>41<sup>-</sup>34<sup>-</sup>KSL cells (HSC2) were transplanted into lethally irradiated mice along with  $1 \times 10^6$  competitor cells. The cells were cultured with SCF and TPO in SF-O3 medium, its supplement, and rHSA for 7 days and then transplanted into lethally irradiated mice along with  $1 \times 10^6$  competitor cells. Recipient mice were followed for 12 months after transplantation. \* $P < .05$  (unpaired *t* test). HSC = hematopoietic stem cells; rHSA = recombinant human serum albumin; SCF = stem cell factor; TPO = thrombopoietin.

(F-12) media. As shown in Figure 3A, F-12 medium supported HSC activity to a significantly greater extent than DMEM or RPMI 1640 medium ( $P < .05$ ), supporting previous observations that the balance in amino acid components plays an important role in HSC maintenance.<sup>33</sup> However, significant differences were not observed among SF-O3, F-12, DF, DR, and DFR media. Next, we compared the SF-O3 supplement, which reportedly contains insulin (I), transferrin (T), and other factors, with I, T, selenium (S), the combination of these components (ITS), and ITS plus ethanolamine (ITS-X). As shown in Figure 3B, individual

supplementation with I, T, or S did not support the maintenance of HSC activities in vitro. Interestingly, the further supplementation of the combination of the 3 additional components (ITS) supported HSC activities. ITS-X, but not ITS, supported the HSCs activities to a greater extent than the SF-O3 supplement. To confirm the effect of ITS-X, LT-HSC activity with F-12 and ITS-X was compared with that of F-12. As shown in Figure 3C, ITS-X supported both ST- and LT-HSC activities. We next compared SF-O3 medium with F-12 medium supplemented with ITS-X. As shown in Figure 3D, F-12 medium supported both ST- and



**Figure 3.** Establishing new serum-free conditions. Various formulations of media and supplements were tested in the presence of rHSA, SCF, and TPO. (A) SF-O3 medium was compared with DMEM, RPMI 1640, Ham F-12 (F-12), a 1:1 mixture of DMEM and F-12 (DF), a 1:1 mixture of DMEM and RPMI 1640 (DR), and a 1:1:1 mixture of DMEM, F-12, and RPMI 1640 (DFR) media. HSC-supporting activity was evaluated 3 months after transplantation by competitive repopulation assay. The percentage of test cells in F-12 was significantly greater than those in DMEM and RPMI ( $*P < .05$ , nonparametric ANOVA). (B) The HSC-supporting activity in the SF-O3 supplement was compared with that in human insulin, transferrin, selenium, the combination of the 3 factors (ITS), and ITS + ethanolamine (ITS-X) 4 months after transplantation by competitive repopulation assay. Forty CD34<sup>+</sup>KSL cells and  $1 \times 10^6$  bone marrow cells were used as the test and competitor cells, respectively. (C) HSC-supporting activity of ITS-X was examined in the presence of F-12, SCF+TPO, and rHSA by competitive repopulation assay. Ten HSC1 cells and  $5 \times 10^5$  bone marrow cells were used as the test and competitor cells, respectively. Recipient mice were followed for 12 months after transplantation. (D) HSC-supporting activity of F-12 medium was compared with that of SF-O3 medium in the presence of SCF+TPO, ITS-X, and rHSA by competitive repopulation assay. Ten HSC1 cells and  $5 \times 10^5$  bone marrow cells were used as the test and competitor cells, respectively. Recipient mice were followed for 12 months after transplantation.  $*P < .05$  (Mann-Whitney test). DMEM = Dulbecco Modified Eagle Medium; HSC = hematopoietic stem cells; rHSA = recombinant human serum albumin; RPMI = Roswell Park Memorial Institute medium; SCF = stem cell factor; TPO = thrombopoietin.




**Figure 4.** Single-cell RT-PCR. (A) The percentages of gene expressing cells in 48 cells (% positive cells) are shown for cytokine receptors and cell-cycle regulators. Single HSC1 cells were analyzed by RT-PCR. Single HSC1 cells were incubated with SCF for 24 hours and analyzed by RT-PCR. Cells were considered as positive cells when threshold cycle values (Ct) were  $<27.65$ . (B) The relative expression levels of cytokine receptors and cell-cycle regulators are shown. The relative expression levels were defined as  $(27.65 - Ct)$ . \* $P < .05$  and \*\* $P < .01$  (unpaired *t* test). HSC = hematopoietic stem cells; SCF = stem cell factor.

LT-HSC activities to a significantly greater extent than SF-O3 medium. We used these established culture conditions as the new standard serum-free culture conditions in the following experiments.

### 3.4. IL-12 receptor expression in HSCs

Reverse transcription-polymerase chain reaction (RT-PCR) was performed on freshly isolated single HSC1 cells. This analysis was also performed on single cells 24 hours after culture in the new standard serum-free medium with SCF because our previous results suggested that few HSC1 cells expressed IL-12 receptor, but its expression was upregulated during in vitro culture.<sup>33</sup> Figure 4 shows the expression of genes selected from a total of 48

genes examined (Supplemental Table 1 and Supplemental Fig. 3, <http://links.lww.com/BS/A4>). Most single HSC1 cells expressed *c-Kit* and *c-Mpl*. Single cells still expressed these cytokine receptors 24 hours after culture. The IL-12 receptors consist of  $\beta 1$  and  $\beta 2$  subunits (*IL-12rb1* and *IL-12rb2*, respectively). The expression of *IL-12rb1* and *IL-12rb2* was detected in 11 and 5 of the 48 HSC1 cells, respectively, though only 1 cell expressed both *IL-12rb1* and *IL-12rb2*. After culture with SCF for 24 hours, 21 cells (44% of the cells) expressed both receptors, suggesting that IL-12 receptor expression was induced by SCF. The upregulation of *Tgfrb1* and *Tgfrb2*, and the common  $\beta$  chain (*Cdf2rb*) were also observed. The upregulation of the IL-12 and TGF- $\beta$  receptors might be tightly associated with cell-cycle progression,



**Figure 5.** Effects of IL-12 reexamined with single-cell culture and serial competitive repopulation. (A) Single-cell culture. Sixty HSC1 cells were cultured with SCF+TPO, SCF+IL-12, or SCF+TPO+IL-12 in the new standard serum-free medium for 7 days, and the number of cells per well was recorded daily. The first, second, and third division kinetics were obtained based on the number of cells per well on days 1-7 of culture (see *Methods* for more detail). Data are shown as the mean  $\pm$  SD of cumulative number of divided cells per 60 cells from 5 independent experiments. There were significant differences in the first, second, and third division kinetics on days 2-7, days 3-7, and days 4-7 between the SCF+TPO and SCF+IL-12 groups. \*\*\* $P < .001$ ; \*\* $P < .01$ ; \* $P < .05$ . There were no significant differences in the first, second, and third division kinetics between the SCF+TPO and SCF+TPO+IL-12 groups (ANOVA). (B) Serial competitive repopulation assay for cultured cells. Ten HSC1 cells were transplanted into lethally irradiated mice, along with  $5 \times 10^5$  bone marrow competitor cells (data shown as freshly isolated cells). Ten HSC1 cells were cultured in the new standard serum-free conditions with SCF+TPO, SCF+IL-12, or SCF+TPO+IL-12 for 7 days and then transplanted into 10 lethally irradiated mice, along with  $5 \times 10^5$  bone marrow competitor cells. Peripheral blood from the recipients was analyzed 1, 4, 6, and 9 months (indicated as 1-1, 1-4, 1-6, and 1-9, respectively) after transplantation. For secondary transplantation, bone marrow cells were collected from all the surviving recipients (8, 9, 6, and 8 mice from the freshly isolated cells, SCF+TPO, SCF+IL-12, and SCF+TPO+IL-12 groups, respectively) and pooled for each group. Then,  $2 \times 10^7$  bone marrow cells were transplanted into lethally irradiated mice. Peripheral blood was analyzed 2, 4, and 6 months (indicated as 2-2, 2-4, and 2-6, respectively) after transplantation. \*\* $P < .01$  and \*\*\* $P < .001$  (nonparametric ANOVA). HSC = hematopoietic stem cells; IL = interleukin; SCF = stem cell factor; TPO = thrombopoietin.

because *Mki67* and members of the cyclin and cyclin-dependent kinase families were expressed after culture with SCF (Fig. 4 and Supplemental Fig. 3, <http://links.lww.com/BS/A4>).

### 3.5. Early division kinetics of HSCs in the presence of IL-12

We noted that a portion of HSC1 cells expressed CD48. Since it has been reported that HSCs do not express CD48,<sup>34,35</sup> we added the marker CD48 for the isolation of HSC1 cells from this experiment (Supplemental Fig. 4, <http://links.lww.com/BS/A5>). We then used serum-free single-cell cultures to examine the first, second, and third division kinetics of HSC1 cells in the presence of either SCF+TPO or SCF+IL-12. As shown in Figure 5A, in the presence of SCF+TPO,  $82.7 \pm 7.9\%$  (mean  $\pm$  SD,  $n = 5$ ) of HSC1 cells underwent the first division within 7 days of culture, and most of the cells subsequently proceeded to the second and third divisions. In the presence of SCF+IL-12,  $75.0 \pm 14.5\%$  (mean  $\pm$  SD,  $n = 5$ ) of HSC1 cells underwent the first division in 7 days of culture. The first division in the SCF+IL-12-treated cells was delayed approximately 2 days compared with the SCF+TPO-treated cells. HSC1 cells never divided in the absence of cytokines. Similarly, HSC1 cells did not divide in the presence of IL-12

alone. Therefore, it was assumed that in the presence of SCF, 1 day or more was required to respond to IL-12; such time was likely required for upregulation of the IL-12 receptor by SCF. The cells slowly and continuously divided with SCF+IL-12 (Supplemental Table 2, <http://links.lww.com/BS/A6>). The addition of IL-12 to the SCF+TPO culture increased the number of cells per well only on later days of culture. Taken together, these data clearly demonstrated that HSCs slowly divide in SCF+IL-12, whereas HSCs rapidly divide in SCF+TPO.

### 3.6. Effect of IL-12 on ST and LT reconstitution potential in HSCs

Using HSC1 cells as test donor cells and our new standard serum-free culture, we again compared the reconstitution activity of the cultured cells by serial competitive repopulation assay, as before. Ten HSC1 cells were directly transplanted into lethally irradiated mice with  $5 \times 10^5$  competitor cells. Ten HSC1 cells were cultured in the new standard serum-free medium with SCF+TPO, SCF+IL-12, or SCF+TPO+IL-12 for 7 days and transplanted into lethally irradiated mice with competitor cells. After 9 months, bone marrow cells from the recipient mice were pooled and transplanted into lethally irradiated mice.

As shown in Figure 5B, cells cultured with SCF+TPO or SCF+TPO+IL-12 showed significantly increased ST reconstitution activities, such as at 1 month after transplantation compared with the freshly isolated cells. Varying degrees of LT reconstitution were observed in mice transplanted with the SCF+TPO, SCF+IL-12, and SCF+TPO+IL-12 cultured cells. However, after secondary transplantation, the reconstitution activity in SCF+IL-12 cultures was significantly greater than in freshly isolated cells and SCF+TPO or SCF+TPO+IL-12 cultures ( $P < .001$ ). All myeloid, B-cell and T-cell lineages were well-reconstituted 6 months after secondary transplantation (Supplemental Fig. 5, <http://links.lww.com/BS/A7>). These data, which are consistent with the data in Figure 1, showed that IL-12 supported LT-HSC self-renewal to a greater extent than TPO. LT-HSCs that responded to TPO and those that responded to IL-12 likely overlapped, because the additional effect of IL-12 to SCF+TPO culture was relatively small.

### 3.7. Transplantation of cells derived from single HSCs in culture

Single HSC1 cells were transplanted into 30 lethally irradiated mice with  $5 \times 10^5$  competitor cells. Single HSC1 cells were cultured in the new standard serum-free medium with SCF+TPO, SCF+IL-12, or SCF+TPO+IL-12 for 7 days. All the cells in an individual well were mixed with competitor cells and individually transplanted into 30 lethally irradiated mice. This was a clonal analysis because single-cell-derived cells were transplanted. Figure 6A shows the reconstitution data for each recipient mouse 1, 4, 7, and 10 months after transplantation. In total, 10, 10, 6, and 7 mice appeared to be positive ( $>0.5\%$  test cells) after transplantation with freshly isolated cells, cells cultured with SCF+TPO, cells cultured with SCF+IL-12, and cells cultured with SCF+TPO+IL-12, respectively. LT reconstitution was detected in 3 mice transplanted with freshly isolated single cells and one mouse each transplanted with cells cultured with SCF+TPO, SCF+IL-12, and SCF+TPO+IL-12, though the myeloid reconstitution levels were very low in all of the positive mice. In these experiments, ST-HSCs were present in isolated HSCs more than LT-HSCs. These data thus indicated that single ST-HSCs can generate one or more ST-HSCs in the presence of SCF+TPO or SCF+IL-12. In another word, SCF+TPO or SCF+IL-12 can support in vitro self-renewal of ST-HSCs.

The same transplantation experiment was repeated. Unfortunately, some of the recipient mice died during the experiment. Ultimately, 7, 3, 2, and 3 recipients appeared to be positive after transplantation with freshly isolated cells, cells cultured with SCF+TPO, cells cultured with SCF+IL-12, and cells cultured with SCF+TPO+IL-12, respectively. Figure 6B depicts the reconstitution data for the freshly isolated cells and cells cultured with SCF+IL-12 obtained from the analysis of each recipient mouse 1, 2, 4, and 6 months after primary transplantation, as well as 2, 4, 6, and 9 months after secondary transplantation. LT-HSC activities from the secondary recipient mice were detected in 4 and 1 mice transplanted with freshly isolated cells and cells from SCF+IL-12 cultures, respectively, compared to none of the mice transplanted with cells from the SCF+TPO and SCF+TPO+IL-12 cultures (data not shown). Myeloid reconstitution was detected until the end of the analysis in 3 mice transplanted with freshly isolated HSC1 cells and 1 mouse transplanted with cells from the SCF+IL-12 culture. These data supported that single LT-HSCs can generate 1 or more LT-HSCs in the presence of SCF+IL-12. In another words, SCF+IL-12 can support in vitro self-renewal of LT-HSCs.

## 4. DISCUSSION


Serum-free culture conditions are essential for controlling the in vitro proliferation and differentiation of HSCs. In this study, we established a simple serum-free culture medium completely composed of defined substances to serve as a standard serum-free culture medium. Commonly used tissue culture protocols often require fetal bovine serum as a source of nutrients. However, serum contains a variety of proteins that have positive and negative effects on cells in culture. This problem persists in serum-free culture because serum albumin fractionated from animal blood, such as BSA, is used in most serum-free media. Lipids, growth factors, hormones, and many other unidentified factors are contaminants in BSA.<sup>27</sup> As a result, this type of serum-free media frequently exhibits batch-to-batch variability; moreover, several formulations are unstable when stored at 4°C for unknown reasons, which likely causes difficulties in reproducing data between different laboratories. Despite their frequent use, the constituent components of commercially available serum-free media are usually not available to the public. In this study, we found that 2 basic components, rHSA and ITS-X, in F-12 medium can sufficiently support in vitro HSCs self-renewal. Hopefully, our new standard serum-free culture conditions will allow us to reproduce and compare ex vivo expansion data not only from our own laboratory but also from other laboratories.

Serial transplantation of cultured cells with SCF+TPO exhibited an initial reconstitution wave (monophasic wave), but serial transplantation of cultured cells with SCF+IL-12 exhibited an initial and second reconstitution waves (biphasic wave). It was very likely that the first reconstitution wave was formed by ST-HSCs derived from ST-HSCs and LT-HSCs, and the second reconstitution wave was formed by LT-HSCs derived from LT-HSCs (Figs. 1, 2, and 5). Basically, similar reconstitution patterns were also observed at the clonal level (Fig. 6).

HSC1 cells were separated from HSC2 cells (Supplemental Fig. 1, <http://links.lww.com/BS/A2>) based on their CD150 expression levels.<sup>34</sup> HSC1 cells were enriched in LT-HSCs, whereas HSC2s were enriched in ST-HSCs (Fig. 2), which is consistent with previous studies.<sup>14,16,35</sup> Notably, HSC1 cells could self-renew in vitro significantly more than HSC2 cells (Fig. 2). However, both ST-HSCs and LT-HSCs continued to coexist among the HSC1 cells (Fig. 6). Because of the subtle changes associated with the sorting gates in flow cytometry, particularly the CD150 gate, more ST-HSCs were sometimes isolated than LT-HSCs, or vice versa. In the single-cell transplantation experiment shown in Figure 6A, where more ST-HSCs were isolated, in vitro self-renewal of ST-HSCs was supported by both SCF+TPO and SCF+IL-12. In the single-cell transplantation experiment shown in Figure 6B, where more LT-HSCs were isolated, in vitro self-renewal of LT-HSCs was supported to a greater extent by SCF+IL-12 than SCF+TPO. These data suggested that only ST-HSCs can generate ST-HSCs, whereas LT-HSCs can generate both ST-HSCs and LT-HSCs. Whereby a monophasic reconstitution wave was created by ST-HSCs and a biphasic reconstitution wave was created by both ST- and TL-HSCs.

Latent HSCs have been defined as HSCs that are able to show reconstitution 4 months or later after transplantation.<sup>14</sup> Since CD150<sup>high</sup> cells are more enriched in latent HSCs than CD150<sup>med</sup> cells, it was relevant to test whether latent HSCs were responsible for the ex vivo expansion of LT-HSCs with SCF+IL-12. LT-HSCs or latent HSCs generated in SCF+IL-12 culture, but not in SCF+TPO culture, might have been responsible for the unique kinetics observed for LT reconstitution by serial transplantation (Figs. 1 and 5). Theoretically, these LT-HSCs may slowly but





**Figure 6.** Transplantation with cells derived in vitro from single cells. (A) Thirty lethally irradiated mice received freshly isolated single HSC1 cells along with  $5 \times 10^5$  competitor cells (freshly isolated single cells). Single HSC1 cells were cultured in the new standard serum-free conditions with SCF+TPO, SCF+IL-12, or SCF+TPO+IL-12 for 7 days, and transplanted along with  $5 \times 10^5$  competitor cells (cultured cells). Peripheral blood from the recipients was analyzed 1, 4, 7, and 10 months after transplantation. (B) Thirty lethally irradiated mice received freshly isolated single HSC1 cells or cells derived from single HSC1 cells in the new standard serum-free culture with SCF+IL-12 for 7 days along with  $5 \times 10^5$  competitor cells. Peripheral blood was analyzed 1 and 2 (indicated as 1-2) and 4 and 6 (indicated as 1-6) months after transplantation. Bone marrow cells were individually collected from 25 and 24 surviving recipients of freshly isolated cells and cultured cells, respectively, and  $2 \times 10^7$  bone marrow cells from each donor were transplanted into a lethally irradiated mouse. Mice were analyzed 2 and 4 (indicated as 2-4) and 6 and 9 months (indicated as 2-9) after secondary transplantation. (A, B) Data only depict the reconstituted mice. Blue columns show the percentage of test cell-derived myeloid cells. Red columns show the percentage of test cell-derived B-lymphoid cells. Green columns show the percentage of test cell-derived CD4 T cells, and purple columns show the percentage of test cell-derived CD8 T cells. HSC = hematopoietic stem cells; IL = interleukin; SCF = stem cell factor; TPO = thrombopoietin.

extensively self-renew after transplantation, but serial transplantation is required to drive them into the cell cycle again.<sup>36</sup>

HSCs have a limited potential to self-renew under physiological conditions, as well as after transplantation.<sup>12,37</sup> This should also theoretically be the case for in vitro HSC self-renewal.

Conceptually, as HSCs divide more, the probability of the loss of self-renewal potential increases. HSCs divided more slowly in the presence of SCF+IL-12 compared with SCF+TPO (Fig. 5A; Supplemental Table 2, <http://links.lww.com/BS/A6>). TPO activates the Jak2/Stat3 and Stat5 signal transduction pathways in

HSCs.<sup>26</sup> Consistent with observations in T cells,<sup>38</sup> IL-12 presumably activates Jak2/Stat4 signal transduction pathways in HSCs. The differences in the signal transduction efficiency should lead to different division rates. The fate decision itself may not necessarily differ between the SCF+TPO and SCF+IL-12 cultures. Slow and continuous division should be an advantage for HSCs to maintain the self-renewal potential because the number of division that they undergo becomes smaller, and sufficient time is given them to repair DNA damage and maintain the telomere length. This hypothesis should be formally verified by further study. Nevertheless, this study demonstrated that IL-12, but not TPO, can be used for the ex vivo expansion of a subset of LT-HSCs.

## ACKNOWLEDGMENTS

This work was supported by grants from the National Key Research and Development Program of China Stem Cell and Translational Research (2017YFA0104903, 2016YFA0100600, and 2017YFA0103400), the Ministry of Science and Technology of China (2015CB964403 and, 2011CB964801), the CAMS Initiative for Innovative Medicine (2016-I2M-1-017 and 2017-I2M-1-015), and the National Natural Science Foundation of China (81470279, 81670105, 81421002, 81400077, and 81500085).

## REFERENCES

- Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. *Exp Hematol* 1997; 25 (5):445–453.
- Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc Natl Acad Sci U S A* 1999; 96 (6):3120–3125.
- Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. *J Exp Med* 2000; 192:1273–1280.
- Ogawa M. Differentiation and proliferation of hematopoietic stem cells. *Blood* 1993; 81 (11):2844–2853.
- Wohrer S, Knapp DJ, Copley MR, et al. Distinct stromal cell factor combinations can separately control hematopoietic stem cell survival, proliferation, and self-renewal. *Cell Rep* 2014; 7 (6):1956–1967.
- Matsunaga T, Kato T, Miyazaki H, Ogawa M. Thrombopoietin promotes the survival of murine hematopoietic long-term reconstituting cells: comparison with the effects of FLT3/FLK-2 ligand and interleukin-6. *Blood* 1998; 92 (2):452–461.
- Miller CL, Eaves CJ. Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability. *Proc Natl Acad Sci U S A* 1997; 94 (25):13648–13653.
- Ema H, Takano H, Sudo K, Nakauchi H. In vitro self-renewal division of hematopoietic stem cells. *J Exp Med* 2000; 192 (9):1281–1288.
- Abe T, Masuya M, Ogawa M. An efficient method for single hematopoietic stem cell engraftment in mice based on cell-cycle dormancy of hematopoietic stem cells. *Exp Hematol* 2010; 38 (7):603–608.
- Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. *Genes Dev* 1990; 4 (2):220–232.
- Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. *Blood* 2002; 100 (4):1302–1309.
- Ema H, Sudo K, Seita J, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. *Dev Cell* 2005; 8 (6):907–914.
- Dykstra B, Kent D, Bowie M, et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. *Cell Stem Cell* 2007; 1 (2):218–229.
- Morita Y, Ema H, Nakauchi H. Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. *J Exp Med* 2010; 207 (6):1173–1182.
- Benz C, Copley MR, Kent DG, et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. *Cell Stem Cell* 2012; 10 (3):273–283.
- Yamamoto R, Morita Y, Oeohara J, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. *Cell* 2013; 154 (5):1112–1126.
- Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. *Cell Stem Cell* 2010; 6 (3):265–278.
- Müller-Sieburg CE, Cho RH, Karlsson L, Huang JF, Sieburg HB. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. *Blood* 2004; 103 (11):4111–4118.
- Carrelha J, Meng Y, Kettyle LM, et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. *Nature* 2018; 554 (7690):106–111.
- Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. *Nat Rev Rheumatol* 2013; 9 (4):252–256.
- Seita J, Asakawa M, Oeohara J, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. *Blood* 2008; 111 (4):1903–1912.
- Jacobsen SE, Veiby OP, Smeland EB. Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. *J Exp Med* 1993; 178 (2):413–418.
- Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. *J Exp Med* 1995; 181 (4):1357–1363.
- Ploemacher RE, van Soest PL, Boudewijn A, Neben S. Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor. *Leukemia* 1993; 7 (9):1374–1380.
- Hirayama F, Katayama N, Neben S, et al. Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. *Blood* 1994; 83 (1):92–98.
- Seita J, Ema H, Oeohara J, et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. *Proc Natl Acad Sci U S A* 2007; 104 (7):2349–2354.
- Ieyasu A, Ishida R, Kimura T, et al. An all-recombinant protein-based culture system specifically identifies hematopoietic stem cell maintenance factors. *Stem Cell Reports* 2017; 8 (3):500–508.
- Ema H, Morita Y, Yamazaki S, et al. Adult mouse hematopoietic stem cells: purification and single-cell assays. *Nat Protoc* 2006; 1 (6):2979–2987.
- Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. *Science* 1996; 273 (5272):242–245.
- Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. *Immunity* 2004; 21 (6):843–851.
- Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. *Blood* 2009; 113 (6):1250–1256.
- Wang X, Dong F, Zhang S, et al. TGF-β1 negatively regulates the number and function of hematopoietic stem cells. *Stem Cell Reports* 2018; 11 (1):274–287.
- Taya Y, Ota Y, Wilkinson AC, et al. Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. *Science* 2016; 354 (6316):1152–1155.
- Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* 2005; 121 (7):1109–1121.
- Kent DG, Copley MR, Benz C, et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. *Blood* 2009; 113 (25):6342–6350.
- Ema H, Uchinomiya K, Morita Y, Suda T, Iwasa Y. Repopulation dynamics of single haematopoietic stem cells in mouse transplantation experiments: Importance of stem cell composition in competitor cells. *J Theor Biol* 2016; 394:57–67.
- Bernitz JM, Kim HS, MacArthur B, Sieburg H, Moore K. Hematopoietic Stem Cells Count and Remember Self-Renewal Divisions. *Cell* 2016; 167 (5):1296–1309.
- Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. *Nature* 1996; 382 (6587):171–174.